Blood Res.  2018 Jun;53(2):172-174. 10.5045/br.2018.53.2.172.

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia

• Kavanagh S
• Bril V
• Lipton JH

• KMID: 2451040
• DOI: http://doi.org/10.5045/br.2018.53.2.172

Abstract

No abstract available.

MeSH Terms

Imatinib Mesylate*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Peripheral Nervous System Diseases*
Imatinib Mesylate

Reference

1. Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017; 93:1296–1313.

2. Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population ≥40 years of age with and without diabetes: 1999–2000 national health and nutrition examination survey. Diabetes Care. 2004; 27:1591–1597.

3. Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015; 29:1123–1132.

4. Chakupurakal G, Etti RJ, Murray JA. Peripheral neuropathy as an adverse effect of imatinib therapy. J Clin Pathol. 2011; 64:456.

5. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003; 19:371–375.

6. Monge KS, Gálvez-Ruiz A, Alvárez-Carrón A, Quijada C, Matheu A. Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case. Saudi J Ophthalmol. 2015; 29:227–231.

7. Ishida T, Akagawa N, Miyata T, et al. Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia. Int J Hematol. 2018; 107:373–377.

8. Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. 2017; 8:86.

9. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006; 12:908–916.

10. Finn AJ, Feng G, Pendergast AM. Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction. Nat Neurosci. 2003; 6:717–723.

11. Wills Z, Marr L, Zinn K, Goodman CS, Van Vactor D. Profilin and the Abl tyrosine kinase are required for motor axon outgrowth in the Drosophila embryo. Neuron. 1999; 22:291–299.

12. Larson RA, Kim DW, Issaragrilsil S, et al. Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f/u) of ENESTnd. Blood (ASH Annual Meeting Abstracts). 2014; 124:Suppl. 4541.

13. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008; 141:745–747.

14. Mustjoki S, Laurinolli T, Ekblom M, et al. Clonal large granular lymphocyte (LGL) expansion associated with dasatinib therapy. Blood. 2007; 110:2938.